Latest Financial Health News

ActivEX Limited has fully repaid its $2.3 million loan to Star Diamond Developments by transferring full ownership of its East Coast Gold and Copper subsidiary, leaving the company debt free and financially strengthened.

FleetPartners Group Limited has announced a $20 million on-market share buy-back, reinforcing its strong balance sheet and commitment to shareholder returns alongside its existing dividend policy.

OM Holdings has declared a special dividend following the sale of its 26% interest in Ntsimbintle Mining, signalling a strategic return of capital to shareholders.

Spenda Limited has successfully raised $1.4 million through a private placement, supported by both new and existing sophisticated investors, including key directors. The funds will fuel the company’s commercialisation efforts and strengthen its working capital position.

Oldfields Holdings Limited remains suspended from ASX trading following its failure to lodge critical half-year financial reports after announcing a capital raising.

Cosmos Exploration Limited has voluntarily suspended its shares from ASX trading as it prepares to announce significant developments involving an Option Agreement and a capital Placement.

Vmoto Limited reported an 18% revenue decline to $46.8 million and a $9.9 million net loss in FY25, while accelerating its transformation into a full-stack electric mobility solutions provider with new global partnerships and product innovations.

Pointerra Limited reported a $2.14 million loss for the half-year ending December 2025 amid a 51% revenue decline, yet the company highlights promising contract wins and a growing recurring revenue base that could drive a turnaround in the second half.

I Synergy Group Limited reported a 15.63% drop in revenue to AUD 0.81 million for FY2025, alongside a 21.5% increase in net loss to AUD 0.34 million, with auditors flagging going concern uncertainties.

Verbrec Limited has reported a remarkable turnaround in its half-year results, posting a $9 million net profit and announcing its first interim dividend in the current period. Strategic acquisitions and a sharp rise in net tangible assets underpin this strong performance.

Clarity Pharmaceuticals has reported a steep 136% increase in its half-year loss to $55.6 million, alongside the closure of its European subsidiary, signaling a challenging period for the ASX-listed biotech.

6K Additive, a US-based metal powder innovator, reports a 3.85% revenue dip to US$17.7 million and narrows net loss to US$17.9 million in its first ASX-listed year. The company plans a fivefold capacity expansion backed by significant government grants and a US$27.4 million loan.